Verve Therapeutics, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG00P33TCZ8
VERV
Verve Therapeutics, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Verve Therapeutics, Inc.
ISIN
US92539P1012
TICKER
VERV
MIC
XNAS
REUTERS
VERV.OQ
BLOOMBERG
VERV US
F&G:
54
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Do., 19.06.2025
Verve Therapeutics
US92539P1012
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve Therapeutics, Inc. (NasdaqGS: VERV) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Verve will receive $10.50 per share in cash, plus ...
Verve Therapeutics
Di., 17.06.2025
Verve Therapeutics
US92539P1012
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of the proposed transaction, Verve shareholders will receive $10.50 per share in cash, plus one non-tradeable contingent value right per share entitling ...
Verve Therapeutics
Di., 17.06.2025
Verve Therapeutics
US92539P1012
The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
I...
Verve Therapeutics
Sa., 26.10.2024
Verve Therapeutics
US92539P1012
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline in the securities class action first filed by the firm.
So what: If you p...
Verve Therapeutics
Mi., 11.09.2024
Verve Therapeutics
US92539P1012
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024. Verve is a “clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular di...
Verve Therapeutics
Mo., 09.09.2024
Verve Therapeutics
US92539P1012
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve Therapeutics” or “the Company”) (NASDAQ: VERV) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defenda...
Verve Therapeutics
Di., 03.09.2024
Verve Therapeutics
US92539P1012
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024. Verve is a “clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular di...
Verve Therapeutics
So., 01.09.2024
Verve Therapeutics
US92539P1012
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve Therapeutics” or “the Company”) (NASDAQ: VERV) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defenda...
Verve Therapeutics
Do., 29.08.2024
Verve Therapeutics
US92539P1012
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
...
Verve Therapeutics
Mi., 28.08.2024
Verve Therapeutics
US92539P1012
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Verve Therapeutics, Inc. (“Verve” or the “Company”) (NASDAQ: VERV) and reminds investors of the October 28, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faru...
Verve Therapeutics
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
